Shares of NovoCure Limited (NVCR) have witnessed a substantial 85% drop from their 52-week high of $95.91, recorded last February, and trade around $14.
The company is focused on the manufacture and commercialization of Tumor Treating Fields devices, designed to extend survival in some of the most aggressive forms of cancer. Its commercially available Tumor Treating Fields (TTFields) devices include Optune Gio and Optune Lua.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.